2nd Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$10,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Agency for Healthcare Research & Quality (AHRQ); SENATE; Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Health Issues HCR

inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); SENATE; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.